Product Name
C12orf65, siRNA
Full Product Name
C12orf65 siRNA (Human)
Product Synonym Names
Probable peptide chain release factor C12orf65 mitochondrial
Product Gene Name
C12orf65 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q9H3J6
Specificity
C12orf65 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human C12orf65 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of C12orf65 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
C12orf65 sirna
siRNA to inhibit C12orf65 expression using RNA interference
Applications Tested/Suitable for C12orf65 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for C12orf65. It may not necessarily be applicable to this product.
NCBI Accession #
NP_001137377.1
[Other Products]
NCBI GenBank Nucleotide #
NM_001143905.2
[Other Products]
UniProt Primary Accession #
Q9H3J6
[Other Products]
UniProt Secondary Accession #
Q8WUC6[Other Products]
UniProt Related Accession #
Q9H3J6[Other Products]
Molecular Weight
12,923 Da
NCBI Official Full Name
probable peptide chain release factor C12orf65, mitochondrial
NCBI Official Synonym Full Names
chromosome 12 open reading frame 65
NCBI Official Symbol
C12orf65??[Similar Products]
NCBI Official Synonym Symbols
SPG55; COXPD7
??[Similar Products]
NCBI Protein Information
probable peptide chain release factor C12orf65, mitochondrial
UniProt Protein Name
Probable peptide chain release factor C12orf65, mitochondrial
Protein Family
Probable peptide chain release factor
UniProt Gene Name
C12orf65??[Similar Products]
UniProt Entry Name
CL065_HUMAN
NCBI Summary for C12orf65
This nuclear gene encodes a mitochondrial matrix protein that appears to contribute to peptide chain termination in the mitochondrial translation machinery. Two different 1 bp deletions (resulting in the same premature stop codon)result in decreased mitochondrial translation, decreased levels of oxidative phosphorylation complexes and encepthalomyopathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2010]
UniProt Comments for C12orf65
C12orf65: May act as a codon-independent translation release factor that has lost all stop codon specificity and directs the termination of translation in mitochondrion. Defects in C12orf65 are the cause of combined oxidative phosphorylation deficiency type 7 (COXPD7). A mitochondrial disease resulting in encephalomyopathy. Clinical manifestations include psychomotor delay and regression, ataxia, optic atrophy, nystagmus and muscle atrophy and weakness. Belongs to the prokaryotic/mitochondrial release factor family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Translation; RNA-binding
Chromosomal Location of Human Ortholog: 12q24.31
Cellular Component: mitochondrion
Molecular Function: translation release factor activity
Biological Process: translational termination
Disease: Combined Oxidative Phosphorylation Deficiency 7
Research Articles on C12orf65
1. our study delineates the broad spectrum of C12orf65 defects and establishes a distinct genotype-phenotype correlation. The obligatory clinical triad is optic atrophy, peripheral neuropathy, and spastic paraparesis.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
